- NCIt
- C4407
Loading cancer entity…
Loading cancer entity…
Clinical trials
46 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06054178 | Identification of Nerves Using Fluorescein Sodium | completed | Phase 2 | 8 | Stanford UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04420689 | Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery | completed | Phase 1 / Phase 2 | 27 | Alume Biosciences, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT02538510 |
| Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery |
| completed |
| Phase 1 / Phase 2 |
| 50 |
| University of WashingtonOTHER |
| 1 |
| Nov 26, 2024 |
| clinicaltrials |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | completed | Phase 1 / Phase 2 | 20 | University of WashingtonOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT01175980 | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2020 | clinicaltrials |
| NCT01604772 | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 1, 2019 | clinicaltrials |
| NCT00859937 | Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 2 | Apr 20, 2018 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00458978 | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 20, 2026source: clinicaltrials